ReviewCurrent heart failure reports2025
Evaluation and Management Principles for Chronic Right Heart Failure and Tricuspid Regurgitation.
Review in Current heart failure reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The right heart perspective in chronic cardiorenal syndrome: the key role of right heart function and tricuspid regurgitation innovation.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewThis review provides an updated summary of the evaluation and management principles of chronic right heart failure (RHF) and tricuspid regurgitation (TR), with a focus on evolving diagnostic approaches and the role of transcatheter tricuspid valve interventions (TTVI). RECENT
findingsChronic RHF and TR frequently coexist and are associated with significant morbidity and mortality. Their interplay is both complex and bidirectional. TR leads to right ventricular (RV) volume overload, while RV remodeling in RHF promotes TR progression, primarily through annular dilatation and leaflet tethering. Advances in imaging modalities, including 3D echocardiography and cardiac magnetic resonance, have improved the evaluation of RV function and TR severity. Additionally, a refined TR grading system, now encompassing "massive" and "torrential" categories, enables more precise severity classification, which is particularly important for evaluating treatment response in device trials. Early identification of TR and RHF is crucial, and optimal management relies on understanding the underlying mechanisms, disease progression, and available treatment options. Although medical therapy for RHF and TR remains limited, TTVI offers an emerging alternative for selected patients. However, identifying appropriate candidates and the optimal timing for intervention remain key challenges. Timely diagnosis of RHF and TR, identification of the underlying causes, and comprehensive risk stratification, along with early referral to a multidisciplinary heart team, are critical for optimizing patient outcomes. Further research is needed to better define selection criteria and timing for TTVI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.